Advanced Filters
noise
Found 2,203 clinical trials

Percutaneous Cryoablation of Low-risk Early Breast Cancer

Expand the current evidence base regarding percutaneous cryoablation of early-stage, low-risk breast tumors, integrated into the standard therapeutic pathway with well-defined follow-up data, as well as data on quality of life. Demonstrate, therefore, that the use of percutaneous cryoablation in the treatment of low-risk breast carcinoma is not inferior to …

50 years of age All Phase N/A

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

Evaluate the safety and efficacy of Pyrotinib in the transition from low-dose to normal-dose regimen for HER2-positive advanced first-line breast cancer

18 - 70 years of age Female Phase 2
A Amparo Garcia-Tejedor, MDPhD

ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.

18 years of age Female Phase N/A
K Kassie DiOrio

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

This phase 1b study investigates the safety and feasibility of combining pre-operative radiation therapy with Cyclin-Dependent Kinase 4 (CDK4/6) inhibitors in participants with hormone receptor positive/HER2 negative (HR+/HER2-) breast cancer. The study aims to assess the benefits of concurrent use of these treatments in a specific participant population, focusing on …

60 years of age Female Phase 1
H Hina Ali, M.D.

Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study

The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins. An …

19 - 90 years of age Female Phase N/A
Y Yan Xu, M.D.

ctDNA Monitoring in Early Breast Cancer

This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.

18 - 80 years of age All Phase N/A
m maylis CARRICABURU, MD

Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.

As much as 50% of patients treated with hormonotherapy (HT) for breast cancer (BC) suffer from osteoarticular pain during treatment. Secondary effects have become a real issue because of their consequences on the patients' quality of life, but also on treatment efficacy and survival when they induce dose reduction or …

18 - 99 years of age Female Phase N/A
E Erin Schubert

FES BPET-DBT in Newly Diagnosed Breast Cancer

Patients with newly diagnosed primary estrogen-receptor (ER) positive breast cancer, with at least one breast lesion that is 1.0 cm in diameter or greater, may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 20 evaluable subjects …

18 years of age Female Phase 0
W Wenjin Yin

Disitamab Vedotin (RC48-ADC) in Breast Cancer

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

years of age All Phase N/A
T Trial Manager

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

The aim of this study is to assess the rates of circulating tumour DNA (ctDNA) in patients treated with surgery for stage 1 breast cancer that is HER2 positive or triple negative. The study will involve collecting blood samples from patients before and after surgery, if patients are enrolled after …

18 years of age All Phase N/A

Simplify language using AI